Importantly, the types of treatments administered did not differ significantly between the anti-MDA5+DM and ASS groups Some patients have already been treated with glucocorticoid or immunosuppressive therapy before enrollment, and there was no significant difference of administered treatments between the anti-MDA5+DM patients and ASS patients. This evidence concerns the gene IFIH1 and dermatomyositis.